Quantcast
Last updated on April 19, 2014 at 13:20 EDT

Latest MedImmune Stories

2012-07-10 06:27:00

BETHESDA, Md., July 10, 2012 /PRNewswire/ -- Summer is a time to play and July 23rd is when The Children's Inn at NIH will get a fabulous new playground thanks to the generosity of MedImmune and KaBOOM! An 8:30 a.m. kickoff ceremony will energize about 150 volunteers from MedImmune, The Children's Inn and organizers from KaBOOM!, who will build the new playground in less than six hours. The playground will be fully accessible to all children and families and will include a spiral...

2012-06-19 02:27:59

SOUTH SAN FRANCISCO, Calif., June 19, 2012 /PRNewswire/ -- AstraZeneca and Rigel Pharmaceuticals, Inc., (Nasdaq: RIGL) today announced an exclusive worldwide license agreement for the global development and commercialization of R256, Rigel's inhaled JAK inhibitor shown to inhibit IL-13 and IL-4 signaling, which is being investigated as a treatment for moderate to severe chronic asthma. In preclinical research, R256 has been shown to reduce airway inflammation and improve lung function....

2012-06-19 02:27:30

CRANBURY, N.J., June 19, 2012 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) today announced that a Phase I clinical trial being conducted by AstraZeneca of AZD2820, a subcutaneously-administered peptide melanocortin-4 receptor partial agonist under development for the treatment of obesity, has been halted. AZD2820 is a clinical candidate under development by AstraZeneca from a collaborative research program with Palatin Technologies. The Phase 1 clinical trial of AZD2820 was...

2012-06-11 02:25:25

BEIJING, June 11, 2012 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, today announced a positive SFDA inspection of the three clinical trial sites being used in the Company's Phase III study of its proprietary inactivated Enterovirus 71 (EV71) vaccine against hand, foot and mouth disease (HFMD). In May 2012, an expert from the Center for Drug Evaluation within the State Food and Drug Administration (SFDA) completed an...

2012-05-15 02:28:13

BEIJING, May 15, 2012 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today its unaudited first quarter financial results for the period ended March 31, 2012. Financial Highlights (year-over-year comparisons to first quarter 2011) Sales increased 30.3% to $6.0 million, with Bilive vaccines sales up 92.4%. Gross margin was 62.2%, which included higher costs due to planned low production level of the animal...

2012-05-11 23:01:10

Medimmune Biologics sued in a class action lawsuit by the California employment law attorneys at Blumenthal, Nordrehaug & Bhowmik for alleged wage and hour overtime violations. The drug sales representative class action suit against the drug company contends that the sales representatives do not qualify for the outside salesperson exemption and are therefore entitled to overtime compensation under the California Labor Code. San Diego, CA (PRWEB) May 11, 2012 On May 9, 2012 the...

2012-05-09 14:23:25

BLUE BELL, Pa., May 9, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE AMEX: INO) today reported financial results for the quarter ended March 31, 2012. Total revenue was $1.7 million for the three months ended March 31, 2012, compared to $3.1 million for the same period in 2011. Total operating expenses were $5.9 million compared to $7.5 million. The net loss attributable to common stockholders was $8.3 million, or $0.06 per share, compared to $2.4 million, or $0.02 per share....

2012-05-02 22:22:03

LUXEMBOURG, May 3, 2012 /PRNewswire/ -- Creabilis SA, a European biotechnology company specialising in the development of treatments for dermatology, inflammation and pain, announces today that Dr Simon Russell has been appointed as Chief Business Officer. Dr Russell joins Creabilis from Novartis Pharma AG where he held a number global strategic marketing roles and most recently Head of Global Marketing for ILARIS (canakinumab). He was previously Head of Strategic...

2012-05-01 06:27:25

BOSTON, May 1, 2012 /PRNewswire/ -- MedImmune, the global biologics arm of AstraZeneca, announced results from a new retrospective database cohort study of 8,443 high-risk infants receiving palivizumab in Medicaid programs across 12 states. Approximately 67% of infants were non-compliant with palivizumab. Non-compliance with the FDA-approved dosing of Synagis® (palivizumab), defined as not receiving at least 5 doses or having dosing gaps, significantly increased likelihood of...

2012-04-27 02:26:48

LONDON, April 27, 2012 /PRNewswire/ -- As AstraZeneca PLC Chief Executive David Brennan steps down, EvaluatePharma Ltd.'s EP Vantage award-winning team of journalists investigates the challenges and strategic options facing by the company. Whoever becomes the new chief executive of AstraZeneca faces a difficult task - choosing a path to pursue to resuscitate the ailing Anglo-Swedish drug maker's growth prospects. Options include a transformative acquisition, an outright...